-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Type 2 diabetes is the most common cause of chronic kidney disease (CKD), and both diabetes and CKD are associated with increased all-cause mortality, infection rates , and cardiovascular events .
In the general diabetic population, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with better glycemic control, greater body weight Relief, lower mortality and cardiovascular event rates were associated
.
Guideline 2 Administering metformin A recent network meta-analysis suggests that different clinical outcomes may occur following the use of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the general diabetic population
Whether the use of GLP-1 receptor agonists is associated with better outcomes compared with the use of DPP-4 inhibitors in the population with diabetes and advanced CKD or ESKD
This retrospective cohort study used data from patients with type 2 diabetes and stage 5 CKD or ESKD from the Taiwan National Health Insurance Research Database
.
The study was conducted between January 1, 2012 and December 31, 2018
This retrospective cohort study used data from patients with type 2 diabetes and stage 5 CKD or ESKD from the Taiwan National Health Insurance Research Database
RESULTS: Of the 27,279 patients included in the study, 26,578 were in the DPP-4 inhibitor group and 701 were in the GLP-1 receptor agonist group
Analysis of primary and secondary outcomes
Primary and secondary outcome analysis Primary and secondary outcome analysisIn conclusion, the results of this study show that GLP-1 receptor agonist treatment is associated with reduced all-cause mortality in patients with type 2 diabetes, advanced CKD and ESKD compared with DPP-4 inhibitors
.
More well-designed prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonists in patients with advanced CKD or ESKD
In conclusion, the results of this study show that GLP-1 receptor agonist treatment is associated with reduced all-cause mortality in patients with type 2 diabetes, advanced CKD and ESKD compared with DPP-4 inhibitors
Reference: Chen J, Wu C, Jenq C, et al.
Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
JAMA Netw Open.
2022;5(3):e221169.
doi :10.
1001/jamanetworkopen.
2022.
1169 JAMA Netw Open.
JAMA doi:10.
1001/jamanetworkopen.
2022.
1169Leave a message here
